Reversible and irreversible monoamine oxidase inhibitors in other psychiatric disorders.
In addition to being effective in depressive disorders, monoamine oxidase inhibitors (MAOIs) have been shown to be effective in controlled studies of patient with panic disorder with agoraphobia, social phobia, atypical depression or mixed anxiety and depression, bulimia, posttraumatic stress disorder (PTSD) and borderline personality disorder. Uncontrolled case reports have noted MAOI efficacy in obsessive-compulsive disorder (OCD), trichotillomania, dysmorphophobia and avoidant personality disorder. Reversible inhibitors of MAO-A (RIMAs) appear safer than the classical irreversible MAOIs since they have less potential to increase blood pressure. They have not been studied as yet, however, in most of the conditions responsive to MAOIs. If RIMAs are found effective in these disorders, they would probably achieve wider use than MAOIs because they are safer and tend to cause fewer side effects.
Liebowitz
M R
MR
New York State Psychiatric Institute, New York 10032.
Hollander
E
E
Schneier
F
F
Campeas
R
R
Welkowitz
L
L
Hatterer
J
J
Fallon
B
B
D000928:Antidepressive Agents / Q000627:therapeutic use*; D001549:Benzamides / Q000627:therapeutic use*; D001883:Borderline Personality Disorder / Q000188:drug therapy; D002032:Bulimia / Q000188:drug therapy; D003131:Combined Modality Therapy; D003866:Depressive Disorder / Q000188:drug therapy; D006801:Humans; D001523:Mental Disorders / Q000188:drug therapy*; D020912:Moclobemide; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use*; D010200:Panic / Q000187:drug effects; D010698:Phobic Disorders / Q000188:drug therapy; D013313:Stress Disorders, Post-Traumatic / Q000188:drug therapy
D000928:Antidepressive Agents; D001549:Benzamides; D008996:Monoamine Oxidase Inhibitors; D020912:Moclobemide